|Bid||43.10 x 3200|
|Ask||0.00 x 800|
|Day's Range||42.77 - 43.50|
|52 Week Range||33.20 - 45.81|
|Beta (3Y Monthly)||0.73|
|PE Ratio (TTM)||10.89|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||1.36 (3.13%)|
|1y Target Est||43.79|
The stock market correction that started in October and has continued in November will encourage investors to buy more conservative stocks. Conversely, Pfizer Inc. (NYSE: PFE) stock is closer to its 52-week highs. Plus, Pfizer stock has a dividend yield of around 3%.
The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug to treat a form of blood cancer in newly diagnosed patients as a combination therapy. Pfizer plans to launch the drug, Daurismo, in the United States by early December with a monthly list price of $16,925, a Pfizer spokeswoman told Reuters. Daurismo was approved for use in adults with acute myeloid leukemia (AML) aged 75 or older or those who have certain health conditions prior to receiving their diagnosis, for whom intensive chemotherapy is not an option, Pfizer said.
Drug giant Pfizer on Wednesday became the sixth big company to request a refund of its campaign contribution to Sen. Cindy Hyde-Smith in light of the Mississippi Republican's controversial "joke" comments about attending a hanging and favoring voter suppression. Pfizer joins Walmart, AT&T, Boston Scientific, Union Pacific, and Leidos in asking for campaign contributions to be returned.
DAURISMO is the first and only Hedgehog pathway inhibitor approved for the treatment of AML
The U.S. Food and Drug Administration said on Wednesday it approved Pfizer Inc's treatment for a rare form of blood cancer in some adults. The drug, Daurismo, was approved for adults with acute myeloid ...
The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Chris Boshoff, senior vice president and head, Immuno-Oncology, Early Development and Translational Oncology, at the Evercore ISI HealthConX Conference on Wednesday, November 28, 2018 at 8:45 a.m. EST. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today. Visitors will be able to listen to an archived copy of the webcast at www.pfizer.com/investors.
On November 20, Pfizer (PFE) closed at $43.53, which was 1.47% lower than its previous closing price. On November 19, Pfizer and Merck KGaA issued a press release announcing unfavorable results from the Phase 3 trial, JAVELIN Ovarian 200, evaluating avelumab in ovarian cancer indication.
As the market grows increasingly turbulent and economic outlooks become more cautious, investors are increasingly buying quality stocks, which by definition are stocks whose companies are not overly reliant on a robust economy for their performance. In the current environment, Walmart Inc. ( WMT), McDonald’s Corp. ( MCD), Pfizer Inc. ( PFE), Procter & Gamble Co. ( PG) and Amgen Inc. ( AMGN) have all received the quality stamp of approval by Citigroup, according to CNBC.
The savage sell-off of US technology stocks broadened into a global market retreat on Tuesday, stoked by investor fears around trade tension, slowing economic growth and weak corporate earnings in the US, Asia and Europe. The big five “Faang” technology stocks that powered much of the post-crisis rally have now had more than $1tn wiped off their value since recent highs, leaving the tech-heavy benchmark Nasdaq heading for its worst quarterly loss since the turmoil that followed Lehman’s collapse in 2008. The Nasdaq Composite index ended a turbulent trading day down 1.7 per cent, nearly wiping out the last of its gains for the year.
The Nasdaq got smacked with its biggest single-session loss in more than three weeks and nearly faced a test of the psychologically important 7000 level.
Diversis Capital Buys Controlling Stake of Tempo Diversis Capital acquired a controlling interest in Tempo, an Icelandic provider of time-tracking, resource-management and budgeting software. Information-technology services company Origo hf.
Pfizer’s (PFE) stock price opened at $36.23 on January 2 and reached $43.51 on November 16, which represents ~20.0% growth year-to-date. Pfizer’s stock price closed at $43.51 on November 16, which represents ~31% growth from its 52-week low of $33.20 on February 9.
My weekend scanning revealed one prominent theme: The healthcare sector is one of the strongest on the Street making many of its constituents the best stocks to buy for the week ahead. Volume patterns are supporting an optimistic view with numerous accumulation days forming after last month’s earnings report.
The selling began early and intensified throughout the day as investors sold nearly everything in sight. Of course, there were a few stocks and sectors that avoided the damage, like Coca-Cola , Verizon and Pfizer , but they were lonely greenshoots in a sea of red. Tech stocks led the bleeding as they have since August, and the headlines were ugly.
pushed higher on Monday despite defying White House demands to control prices and a broader market selloff. Caitlin Oakley, a spokeswoman for the U.S. Department of Health and Human Services, lambasted the company's move in a statement to Real Money. "Actions announced Friday on list prices further illustrate the perverse incentives of America's drug pricing system," she wrote.
Pfizer and Germany's Merck KGaA said their immunotherapy regimen failed as an ovarian cancer treatment, underscoring "the significant challenges these women face." Pfizer stock rose.
The current market conditions could bode well for drug stocks into the coming quarters should corrections continue. "The market is telling us what we already know, people are scared of a recession and an escalating trade war and are therefore positioning more defensively," Action Alerts Plus analyst Zev Fima told Real Money. The companies will also be buoyed because of the inelastic demand for their products.
HHS spokeswoman Caitlin Oakley did not hold back in a statement to Real Money. "Actions announced Friday on list prices further illustrate the perverse incentives of America's drug pricing system," she wrote. "Drug companies raising their prices and offsetting them with higher rebates benefits everyone but the consumer, who routinely pays out of pocket based on list price.
The major indices continue to see extreme selling pressure. Breadth is running about 1,750 gainers to 5,350 decliners and new 12-month lows are over 300. There is a steady diet of bad news and no immediate technical support until the lows of October are retested.
Association for Accessible Medicines CEO Chip Davis discusses the Trump administration’s fight to lower prescription drug prices.